The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial [17] was a pioneer phase 3 study conducted among patients with a history of ASCVD (myocardial infarction, non-hemorrhagic stroke, or symptomatic peripheral artery diseases presenting with additional risk factors) on a regimen of a 20-mg minimum daily dose of atorvastatin and LDL-C levels >70 mg/dL. Here, PCSK9 is linked to atherosclerosis.